Medication info

Boniem Injection (Ibandronic Acid Sodium Hydrate)

Prescription medicationSolutionIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
Shinpoong Pharmaceutical Co., Ltd.
Appearance
A colorless and transparent solution contained in a pre-filled syringe with a single-use injection needle attached.
Packaging
3 milliliters / vial X 1
Approval status
Active

MFDS item code 201306542 · Approved 2013.03.29 · Insurance code 648506911

Summary

Main use
Treatment of osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take supplemental calcium and vitamin D. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment: No dose adjustment is necessary. No dose adjustment is necessary in patients with mild or moderate renal impairment who have a serum creatinine of 200 µmol/L(2.3mg/dL) or less, or a creatinine clearance of 30ml/min or more. Use of this drug is not recommended in patients with a serum creatinine greater than 200 µmol/L(2.3mg/dL) or a creatinine clearance of less than 30ml/min because clinical experience is insufficient. Elderly: No dose adjustment is necessary.
Child administration
Efficacy and safety have not been studied in children 18 years of age or younger.

Ingredients

Manufacturer
Shinpoong Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication helps increase bone strength and bone density to reduce the risk of fractures when osteoporosis occurs in postmenopausal women. It is used to relieve pain and discomfort due to osteoporosis and improve mobility in daily life.

How it is given

Adult administration

Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take supplemental calcium and vitamin D. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible, then continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment: No dose adjustment is necessary. No dose adjustment is necessary in patients with mild or moderate renal impairment who have a serum creatinine of 200 µmol/L(2.3mg/dL) or less, or a creatinine clearance of 30ml/min or more. Use of this drug is not recommended in patients with a serum creatinine greater than 200 µmol/L(2.3mg/dL) or a creatinine clearance of less than 30ml/min because clinical experience is insufficient. Elderly: No dose adjustment is necessary.

Child administration

Efficacy and safety have not been studied in children 18 years of age or younger.

Precautions

This medication must be administered intravenously and must be injected very carefully, as injection into the artery or near the vein can cause tissue damage. It should not be used in patients with hypersensitivity to this medication or untreated hypocalcemia. During use, gastrointestinal symptoms such as dyspepsia, abdominal pain, nausea, and diarrhea may occur, and musculoskeletal symptoms such as myalgia or arthralgia have also been reported. Additionally, flu-like symptoms may temporarily appear after injection, which is usually mild and resolves on its own over time. Before administering this medication, any hypocalcemia or bone and mineral metabolism disorders must be treated, and sufficient calcium and vitamin D intake is required. Patients undergoing dental treatment or with poor oral hygiene are at risk for serious side effects such as osteonecrosis of the jaw, thus it is recommended to have a dental examination before administration. Long-term use of this medication may increase the risk of atypical fractures in the femur; therefore, prompt consultation with a physician is necessary if there is leg pain. In cases of overdose, it may affect the kidneys and liver, requiring careful monitoring, and appropriate treatment is needed if severe hypocalcemia occurs. Pregnant or breastfeeding women are advised not to use this medication as its safety has not been established. This medication has a low risk of metabolic interactions with other drugs, but patients with renal impairment require regular checks. Syringes and needles should not be reused and must be disposed of safely, kept out of reach of children.

Side effects

  • Gastritis
  • diarrhea
  • abdominal pain
  • indigestion
  • nausea
  • constipation
  • musculoskeletal pain
  • joint pain
  • muscle pain
  • influenza-like illness
Show 70 more
  • fatigue
  • headache
  • rash
  • bone pain
  • weakness
  • injection site reaction
  • phlebitis
  • thrombophlebitis
  • hypersensitivity reaction
  • angioedema
  • facial swelling
  • edema
  • hives
  • uveitis
  • episcleritis
  • scleritis
  • anaphylactic reaction
  • shock
  • exacerbation of asthma
  • Stevens-Johnson syndrome
  • erythema multiforme
  • vesicular dermatitis
  • atypical fracture of the lower limb
  • intertrochanteric femur fracture
  • muscle pain
  • joint pain
  • indigestion
  • influenza-like illness
  • musculoskeletal pain
  • headache
  • gastritis
  • nausea
  • fatigue
  • dizziness
  • fever
  • hypothyroidism
  • peripheral neuropathy
  • hearing loss
  • dyspnea
  • skin peeling
  • multiple organ failure
  • death
  • dizziness
  • fracture
  • optic nerve atrophy
  • lower motor neuron lesions
  • tremor
  • unspecified gastrointestinal disorders
  • benign gastrointestinal neoplasm
  • toothache
  • hyperventilation
  • cough
  • laryngitis
  • vaginitis
  • menopausal symptoms
  • multiple organ failure
  • death
  • insomnia
  • anxiety
  • tinnitus
  • hearing loss
  • hypothyroidism
  • lipoma
  • ocular hemorrhage
  • heart failure
  • urinary disorders
  • hematuria
  • skin peeling
  • sensory loss
  • acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent contact with air, and it is safe to store at room temperature between 1 and 30 degrees Celsius.

Appearance and packaging

Appearance

A colorless and transparent solution contained in a pre-filled syringe with a single-use injection needle attached.

Package unit

3 milliliters / vial X 1

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.